A comparative analysis of the efficacy of intrauterine misoprostol in conjunction with oxytocin versus oxytocin monotherapy for the prophylaxis of primary postpartum haemorrhage.

Abstract

Objectives: To determine the effectiveness of intrauterine misoprostol along with oxytocin versus oxytocin monotherapy for the prevention of primary postpartum haemorrhage.

Methods: The quasi-randomised controlled trial took place at the Akbar Niazi Teaching Hospital, Islamabad, Pakistan, from February to August 2021, and comprised women who underwent lower segment caesarean section and at fullterm pregnancy who had risk factors for experiencing postpartum haemorrhage. The subjects were randomised into experimental group A and control group B. Group A subjects received both misoprostol and oxytocin, while those in group B received oxytocin only. Data was analysed using SPSS 26.

Results: Of the 120 subjects, 60(50%) were in group A with mean age 28.72±5.82 years and mean gestational age 38.02±1.1 weeks. The remaining 60(50%) subjects were in group B with mean age 29.47±4.72 years and mean gestational age 37.50±1.5 weeks. Group A subjects had fewer changes in haemoglobin levels post-operation than those in group B (p<0.05). The number of operative towels used, contractility time of the uterus, and need for other drugs to control haemorrhage were significantly different in group A compared to group B.

Conclusion: Misoprostol along with oxytocin was found to be more effective in reducing blood loss in patients with postpartum haemorrhage.